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RNA interference-mediated knockdown of p21
WAF1 enhances
anti-tumor cell activity of oncolytic adenoviruses
M Shiina, MD Lacher, C Christian and WM Korn
Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Helen Diller Family
Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA
The ability of oncolytic adenoviruses to replicate in and lyse cancer cells offers a potential therapeutic approach. However,
selectivity and efficacy of adenovirus replication need to be improved. In this study, we present that loss of p21
WAF1 promotes
adenovirus replication and more effective cell killing. To test our hypothesis, we took HCT116 colon cancer cell lines carrying
deletions of either p21
WAF1 or p53, and infected these cell lines with wild-type adenovirus (WtD) or the oncolytic adenoviruses,
ONYX-015 and Delta-24. We found that WtD, ONYX-015 and Delta-24 induced stronger cytopathic effects in HCT116 p21 / 
cells compared with HCT116-WT cells. This was accompanied by increased virus production. siRNA-mediated knockdown of
p21
WAF1, and similarly of p27
KIP1, in HCT116-WT cells also enhanced replication of and cell killing by these viruses. Furthermore,
we found that TE7, an esophageal carcinoma cell line, also showed a strong cell-killing effect and virus production when p21
WAF1
expression was suppressed by RNA interference before adenoviruses infection. Also, H1299 and DU-145 cells transfected with
p21
WAF1 siRNA showed higher virus production after ONYX-015 and Delta-24 infections. These observations suggest that p21
WAF1
plays a role in mediating replication of oncolytic viruses with potential implications for adenoviral therapy of cancer.
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Introduction
Replication-selective oncolytic adenoviruses are promis-
ing new therapeutic anti-cancer agents that selectively
replicate in and lyse cancer cells while leaving normal cells
unharmed.
1–3 One strategy for achieving tumor selectivity
is to mutate or partially delete E1 genes that are required
for viral replication in normal cells but are dispensable in
cancer cells.
4 For example, the adenovirus mutant dl1520/
ONYX-015 does not express the E1B-55K protein, which
theoretically restricts its replication to p53-defective
tumor cells.
5 Although indeed aberrations within the
p53 pathway seem to contribute to ONYX-015’s selectiv-
ity, it is now clear that additional, p53-independent effects
are important for its tumor selectivity.
6,7 Another
oncolytic adenovirus, Delta-24, contains a 24-bp deletion
in the viral E1A gene, which prevents binding of E1A to
the RB protein.
8 Normal cells with functional RB are thus
unable to support Delta-24 replication, whereas tumor
cells with non-functional RB support viral replication.
The replicative potential of oncolytic viruses is an
important factor determining the therapeutic efficacy of
this approach, as mathematical modeling has shown.
9 To
improve oncolytic potency and efficacy of therapeutic
adenoviruses, enhancing the replicative potential, whereas
maintaining tumor selectivity, would therefore be im-
portant. A detailed understanding of the molecular
mechanisms dictating oncolytic virus replication in
tumors cells is a prerequisite for reaching this goal.
p21
WAF1 and p27
KIP1 are members of the CIP/KIP
family of cyclin-dependent kinase inhibitors (CKIs) that
show a high degree of sequence homology at their N-
terminal portions, enabling them to bind to both cyclin-
dependent kinases (Cdks) and cyclins. Although CIP/KIP
inhibitors bind and inhibit complexes containing cyclin D,
E and A, the main target seems to be the cyclin E–Cdk2
complex. Binding of CKIs to this complex blocks
progression from G1 to S phase.
10,11 In agreement with
the role of p27
KIP1 as a negative regulator of cell cycle
progression, its loss or cytoplasmic mislocalization
usually correlates with increased tumor aggressiveness
and a poor clinical outcome in various types of human
cancers, with rare exceptions, for example in some breast
cancers, where overexpression of p27
KIP1 has been
correlated with rapidly proliferating carcinomas.
12,13
Oncolytic adenoviruses such as ONYX-015 replicate
most efficiently when the target cells are in the S-phase of
the cell cycle.
14 It is therefore conceivable that host
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CGT C CGTO Op pen enproteins important for cell cycle regulation affect the
efficacy of virus replication. It is therefore interesting to
note that recently valproic acid, a commonly used anti-
epileptic drug, was found to have potential anti-cancer
activity
15 and to inhibit adenoviral replication and viral
spread by inducing p21
WAF1 expression.
16 Here, we
investigate the role of p21
WAF1 and p27
KIP1 as regulators
of replication of wild-type adenovirus and the therapeutic
oncolytic adenoviruses, ONYX-015 and Delta-24, in
cancer cells and explore the possibility to increase virus
replication through inhibition of these CKIs.
Materials and methods
Cell lines
HCT116 wild-type (HCT116-WT) cells and their deriva-
tives, HCT116 p21 / 
17 and HCT116 p53 /  (clone
379.2),
18 carrying homozygous deletions of p21 and p53,
respectively, were kindly provided by Dr Bert Vogelstein
(John Hopkins Cancer Center, Baltimore, MD). HCT116
cells were cultured in McCoy’s 5A medium (UCSF Cell
Culture Facility, San Francisco, CA) supplemented with
10% fetal bovine serum (FBS) (Valley Biomedical
Products, Winchester, VA). The pancreatic cancer cell
line MIA PaCa-2 was generously provided by Dr Martin
McMahon (Cancer Research Institute, UCSF Compre-
hensive Cancer Center, San Francisco, CA). The lung
cancer cell line, H1299, was a gift from Dr David M
Jablons (Cancer Research Institute, UCSF Comprehen-
sive Cancer Center). The prostate carcinoma cell line,
DU-145, was a gift from Dr Colin Collins (Cancer
Research Institute, UCSF Comprehensive Cancer Cen-
ter). HEK-293 (human embryonic kidney), DU-145 and
MIA PaCa-2 cells were grown in Dulbecco’s Modified
Eagle’s Medium (UCSF Cell Culture Facility) supple-
mented with 10% FBS. The esophageal carcinoma cell
line TE7 and H1299 were maintained in RPMI-1640
(UCSF Cell Culture Facility) supplemented with 10%
FBS.
Adenoviruses
Viruses included wild-type adenovirus (WtD), the E1B-
55K-deficient adenovirus mutant ONYX-015
19 and
Delta-24, which carries a 24-bp deletion in the viral E1A
gene
8 (kindly provided by Dr Juan Fueyo, University of
Texas MD Anderson Cancer Center, Houston, TX).
Adenoviruses were amplified in HEK-293 cells, purified
using the Adenopure Purification Kit (Puresyn, Malvern,
PA) and their titers determined using the Adeno-X Rapid
Titer Kit (Clontech, Mountain View, CA). Ad-Luc, a
firefly luciferase encoding non-replicating adenovirus, was
used for quantification of virus uptake.
20
Quantification of Adeno-fiber gene copies by
quantitative real-time PCR
For the quantification of cellular uptake of the virus,
HCT116-WT or HCT116 p21 /  cells were infected with
Ad-Luc for 24 and 48h. DNA was purified from cell
lysates by using the DNeasy Tissue Kit (Qiaqen, Valencia,
CA), and adenovirus fiber and GAPDH genes were
subjected to Taqman PCR (performed by the University
of California, San Francisco, Comprehensive Cancer
Center Genome Core; San Francisco, CA). The adeno-
virus fiber probe (50-FAM-AACCCCGTGTATCCATA
TGACACGGAAA-TAMRA-30) was designed to anneal
to the target between the sense primer (50-CATGTTG
TTGCAGATGAAGCG-30) and the anti-sense primer (50-
GGCACAGTTGGAGGACCG-30). For GAPDH, the
probe (50-FAM-ATGGCACCGTCAAGGCTGAGAAC
G-BHQ1-30) was used in combination with the sense
primer (50-ATTCCACCCATGGCAAATTC-30) and the
anti-sense primer (50-TGGGATTTCCATTGATGAC
AAG-30).
Cell viability
For this assay, HCT116 cell lines were seeded in 96-well
plates overnight and infected with WtD, ONYX-015 or
Delta-24 at multiplicities of infection (MOIs) of 0, 1, 3, 5,
10 or 30. Cell viability was measured by using the
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS) (Promega, Madison, WI) at 2–4 days post
infection. Cell viability was expressed as percentage of the
untreated medium control (that is, MOI¼0). Micropho-
tographic pictures were taken at 72h after infection with
WtD, ONYX-015 or Delta-24 at MOI of 1.
siRNA experiments
HCT116-WT, HCT116 p21 /  and HCT116 p53 / 
cells were transfected with pre-designed ON-TARGET-
plus siRNAs (Dharmacon, Chicago, IL). For p21
WAF1,
30nM of CDKN1A cat # J-003471-11 and J-003471-12
(oligonucleotides (oligos) #11, #12 hereafter) and
for p27
KIP1 30nM of CDKN1B cat # J-003472-05 and
J-003472-08 (oligos #5, #8 hereafter) were used. H1299,
DU-145, MIA PaCa-2 and TE7 cells were transfected
with 50nM of p21
WAF1 siRNA #12. siCONTROL non-
targeting siRNA (Dharmacon) was used as negative
control. Reverse transfections were carried out by first
adding the siRNA/Lipofectamine complexes into empty
wells of 6-well plates followed by the addition of the cells.
Transfections were carried out according to the guidelines
for the Lipofectamine RNAiMax reagent (Invitrogen,
Carlsbad, CA). At 48h after transfection, cells were lysed
for immunoblotting or were re-seeded in 96-well plates for
infection with WtD, ONYX-015 or Delta-24 at an MOI
of 1. Thereafter, viability of HCT116 cells was quantified
by the CellTiter 96 Aqueous One Solution Cell Prolifera-
tion Assay (MTS) (Promega) as described above. A t-test
was used for statistical analysis.
Viral replication assays
HCT116 cell lines were infected with WtD, ONYX-015 or
Delta-24 at an MOI of 1 in 6-well plates. At 72h after
infection, HCT116 cells were scraped into culture medium
and lysed with three cycles of freezing (dry ice-ethanol
bath) and thawing (371C water bath). The cell lysates were
cleared by centrifugation. Supernatants were serially
diluted in cell culture medium containing 10% FBS and
used to infect HEK-293 cells (passaged no more than six
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after infection by immunostaining for a viral protein
(hexon) with the AdEasy Viral Titer Kit (Strategene, La
Jolla, CA) following the manufacturer’s instructions.
HCT116-WT, HCT116 p53 /  cell lines were
transfected with p21
WAF1 or p27
KIP1 for 48h and infected
with WtD, ONYX-015 or Delta-24 at MOI of 1 before
virus replication assay. A t-test was used for statistical
analysis.
Immunoblotting
Cells were lysed in RIPA buffer (Sigma-Aldrich, St Louis,
MO) supplemented with Complete/Mini protease
inhibitor cocktail (Roche, Indianapolis, IN). Cell lysates
were separated on NuPAGE 4–12% polyacrylamide
Bis–Tris gels/MES-SDS buffer (Invitrogen) and trans-
ferred onto Immobilon-P polyvinylidene fluoride (PVDF)
membranes (Millipore, Billerica, MA). Membranes were
blocked in 5% milk/TBS containing 0.1% Tween 20
(TBST). Primary mouse monoclonal antibodies used
were anti-p21 (sc-6246, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), anti-p53 (sc-126, Santa Cruz
Biotechnology) and anti-b-actin (Sigma-Aldrich).
Primary rabbit polyclonal antibody used was anti-p27
(sc-776, Santa Cruz Biotechnology). Both primary and
secondary antibodies were diluted in 0.5% milk/TBST.
Secondary antibodies were horseradish peroxidase-con-
jugated and reactive proteins were visualized with
enhanced chemiluminescence (ECL) (Amersham
Pharmacia, Piscataway, NJ).
Results
Effect of loss of p21
WAF1 on cell killing by oncolytic
adenoviruses
To determine the effect of p21
WAF1 on cell killing,
HCT116-WT, HCT116 p21 /  and HCT116 p53 / 
cells were infected with different adenoviruses and cell
viability was assessed. Dose-escalation experiments
showed that WtD and ONYX-015 at MOIs of 1–30
induced a clearly stronger cytopathic effect in the
HCT116 p21 /  cell line compared with HCT116-WT
cells (Figure 1). As observed in other cell types, the
stronger cell-killing potential of WtD compared with
ONYX-015 was preserved in this setting.
21 By three days
after WtD infection at an MOI of 1, the viability of
HCT116 p21 /  cells was reduced to 11% compared
with 38% of HCT116-WT cells (Figures 1a and d). For
ONYX-015, 3 days after infection with an MOI of 1, the
viability of HCT116 p21 /  cells was reduced to 23%
compared with 69% of HCT116-WT cells (Figures 1b
and d). The viability of HCT116 p53 /  cell line showed
similar results as HCT116-WT cells (Figures 1a–d),
suggesting that the cell-killing effect may be independent
of p53. Delta-24 adenovirus also showed a more potent
cell-killing effect on cells lacking p21
WAF1 with 32% of
viable HCT116 p21 /  cells compared with 72% of
viable HCT116-WT cells at MOI of 1 (Figures 1c and d).
Increased virus production in HCT116 p21 /  cells
As the increase in killing of HCT116 p21 /  cells could
have been a result of enhanced apoptosis and not of virus-
mediated cell lysis, we examined the ability of adenovirus
to replicate and to produce viable progeny in HCT116-
WT, HCT116 p21 /  and HCT116 p53 /  cells. At 72h
after cells were infected with WtD, ONYX-015 and Delta-
24 at an MOI of 1, virus production was determined by
using the AdEasy Viral Titer Kit (Figure 2). For WtD,
ONYX-015 and Delta-24, HCT116 p21 /  infection
resulted in 2.5, 4.5 and 2.1-fold, respectively, increase in
viral production compared with HCT116-WT cells,
respectively. HCT116 p21 /  cells had approximately
twofold more viruses produced compared with HCT116
p53 /  for all viruses used in this study.
Adenovirus entry into cancer cells is not affected by loss
of p21
WAF1
To ensure that differences in cell killing between HCT116-
WT and HCT116 p21 /  cells were not related to
differences affecting the viral entry mechanism (for
example, differences in receptor expression), we compared
uptake of the non-replicating Ad-Luc adenovirus
19 in
these cell lines. As the constitutive promoter driving the
luciferase reporter gene in principle could be differentially
expressed in the different HCT116 cell lines, we quantified
the cellular uptake of adenovirus in terms of copy
numbers of the adenovirus fiber gene, normalized by
GAPDH gene copy numbers, using TaqMan PCR. We
found that the number of copies of adenovirus fiber taken
up by the cells was the same for both cell lines after 24 and
48h after infection (data not shown), thus indicating that
loss of p21
WAF1 does not affect adenoviral entry into
these cell lines.
Enhanced tumor cell killing by oncolytic adenoviruses
following knockdown of p21
WAF1 or p27
KIP1 by
small-interfering RNAs
To determine if indeed the loss of p21
WAF1 promotes
adenovirus-mediated cell killing and is not an artifact
related to the HCT116 p21 /  cell line, we silenced
p21
WAF1 in HCT116-WT cells and evaluated whether cell
killing and virus production were also enhanced in this
system. As p21
WAF1 is functionally related to p27
KIP1,
10
we expanded our analysis also by knockdown of p27
KIP1.
The HCT116-WT, HCT116 p21 /  and HCT116
p53 /  cell lines were transfected with p21
WAF1-specific
siRNAs, p27
KIP1-specific siRNAs or non-targeting con-
trol siRNAs, then infected with adenoviruses. Efficient
knockdown of p21
WAF1 or p27
KIP1 was confirmed by
Western blot analysis (Figures 3a–d), whereas transfec-
tion of non-targeting control siRNAs had no effect. To
test the effect of the p21
WAF1 or p27
KIP1 siRNAs on virus-
mediated cell killing, cell viability was measured following
virus infection in the presence or absence of the siRNAs.
At 72h after WtD infection, the viability of HCT116-WT
cells transfected with p21
WAF1 siRNA (oligo #11)
decreases to 54% compared with the non-targeting
negative siRNA control. Viability of HCT116-WT cells
transfected with another p21
WAF1 siRNA (oligo #12) or
RNA interference-mediated knockdown of p21
WAF1
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Figure 1 Determination of cell viability. HCT116-WT, HCT116 p21 /  and HCT116 p53 /  cells were infected at multiplicities of infection
(MOIs) of 0–30 for 72h with wild-type adenovirus (WtD) (a), ONYX-015 (b) or Delta-24 (c). Cell viability was measured using the CellTiter 96
Aqueous One Solution Cell Proliferation Assay (MTS) assay at different times and expressed as percentage of the untreated medium control.
Data represent means of triplicate experiments. Error bars indicate s.d. Cytophatic effect (d) in HCT116-WT, HCT116 p21 /  or HCT116
p53 /  cells infected with WtD or ONYX-015 or Delta-24 at an MOI of 1 for 72h.
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KIP1 siRNA (oligos #5 and #8) decreased to B65%
after WtD infection (Figure 3e). Similarly to WtD, the
oncolytic effect of ONYX-015 increased when p21
WAF1
was silenced (Figure 3f), although p27
KIP1 knockdown
showed no effect on cell killing by ONYX-015 (Figure 3f).
Delta-24 reduced the viability of the HCT116-WT cells to
65% when p21
WAF1 siRNAs (oligos #11 and #12) or
p27
KIP1 siRNA (oligos #5 and #8) were used (Figure 3g).
HCT116 p53 /  transfected with p21
WAF1 siRNAs
(oligos #11 and #12) (Figures 3h–j) showed no oncolytic
effect with any of the adenoviruses. It suggests that it may
have a p53-dependent cell-killing effect when p21
WAF1 are
silenced in this cell line. Only a reduction of the viability
to 60% after Delta-24 was observed after transfection of
p27
KIP1 siRNA (oligos #5 and #8) in HCT116 p53 / 
cells.
As expected, the viability of HCT116 p21 /  cells
transfected with p21
WAF1 siRNA (oligo #12) did not
change after infection with any of the adenoviruses,
compared with the non-targeting negative control siRNA
(data not shown), confirming that the observed effects are
resulting from target knockdown and not from off-target
effects. Also, all three viruses had no change in cell killing
compared with non-targeting negative control in HCT116
p21 /  cells transfected with p27
KIP1 siRNAs (data not
shown).
Increased viral particle production following
knockdown of p21
WAF1
To confirm that the increase in cell killing was indeed
related to increased virus production, a measure of virus
replication, production of viral particles was determined
using the AdEasy Viral Titer kit (Stratagene). In HCT116-
WT, we found an increase of WtD, ONYX-015 and
Delta-24 production (Figures 4a–c), after transfection
with p21
WAF1 siRNA (oligos #11 and #12) compared with
the non-targeting negative siRNA control. Similarly, an
increase in production of all viruses was found after
transfection of p27
KIP1 siRNA (oligos #5 and #8). These
results suggested that p21
WAF1 and p27
KIP1 are playing a
role in modulating efficacy of virus replication.
In HCT116 p53 /  cells, increased production of WtD
was measured after suppression of p21
WAF1 and p27
KIP1
by siRNAs (Figure 4d). Although less efficient than WtD,
increased virus production was observed when p21
WAF1
and p27
KIP1 were silenced and infected with ONYX-015
or Delta-24 for 72h (Figures 4e and f). These results
suggest that p53 plays an important role in virus
replication and oncolytic effect after knockdown
of p21
WAF1 and p27
KIP1. The exact mechanism by which
p21
WAF1/p27
KIP1 suppress replication of oncolytic
adenoviruses remains unclear and is under investigation.
In agreement with our observations made in cell-killing
effect in HCT116 p21 /  cells, knockdown of p21
WAF1
and p27
KIP1 did not affect virus production (data not
shown).
p21
WAF1 regulates replication of adenoviruses in human
tumor cell lines
To find out whether the observed effects resulting from
p21
WAF1 knockdown on adenovirus replication are
specific for HCT116 cells, we expanded our analysis to
TE7 cells, an esophageal carcinoma cell line, as this tumor
type is a possible target for adenoviral therapies. Viability
of this cell decreases to 28, 71 and 59% after p21
WAF1
knockdown (oligo #12) and adenovirus WtD, ONYX-015
and Delta-24 infection, respectively, compared with
untreated cells (Figures 5a and b).
To address the role of p53 in cells lacking functional
p53 expression, we used H1299, p53 null, and DU-145,
non-functional p53. Interestingly, no effect of p21
WAF1
siRNA on cell killing or virus production were observed
for both cells lines infected with WtD (Figures 5a, c, d and
6). For H1299 cells infected with oncolytic adenoviruses,
ONYX-015, no increase in cell-killing effect was
observed, although there was an increased viruses
production after p21
WAF1 knockdown (oligo #12)
(Figures 5c and 6). For DU-145 cells, a slightly decrease
in the viability and increase in virus production were
observed after p21
WAF1 knockdown (oligo #12) and
infection of ONYX-015 and Delta-24 (Figures 5d and c).
MIA PaCa-2 cells, a human pancreatic cancer cell line
that does not express p21
WAF1,
22 showed extensive
cell killing when infected with WtD regardless of the
presence or absence of p21
WAF1 siRNA (oligo #12)
(Figures 5a, e and 6).
Discussion
Oncolytic viruses are designed to replicate in and lyse
cancer cells on the basis of genetic changes present in
tumor but not normal cells. A variety of such agents were
developed. For example, H101, a variant of ONYX-015,
has been approved for the use in head-and-neck cancer by
the Chinese authorities.
23 Theoretically, this therapeutic
platform has the advantage of great flexibility. For
example, oncolytic adenoviruses can be modified
(‘armed’) to express therapeutic genes or changed in their
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2,24 These approaches rely on viral replica-
tion, the capacity of the virus to self-amplify and spread in
the tumor. Our data show that loss of p21
WAF1 promotes
adenovirus replication and more effective cell killing
compared with cells expressing p21
WAF1. We took
advantage of a derivative of the human HCT116 colon
cancer cell line harboring a homozygous deletion of
p21 / , and found that wild-type adenovirus and
ONYX-015 replicate more efficiently in tumor cells
lacking p21
WAF1 expression compared with wild-type
cells (Figure 1). This finding was confirmed through our
experiments using small-interfering RNAs directed
against p21
WAF1and p27
KIP1, which increased virus-
mediated cell killing and production of viable viral
particles in HCT116 cells expressing wild-type p53
(Figures 3 and 4). In agreement with our findings, Hoti
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Figure 3 Viability of HCT116 cell lines transfected with p21
WAF or p27
KIP1 siRNAs before adenovirus infection. HCT116-WT or HCT116 p53 / 
were transfected with p21
WAF1 or p27
KIP1 siRNAs. Adenovirus infections were carried out 48h later. For HCT116 cells, viability was assessed
72h after addition of the wild-type adenovirus (WtD) or Delta-24 adenoviruses or 94h for ONYX-015. For HCT116 p53 /  cells, viability was
assessed 72h after addition of the WtD or 94h for ONYX-015 and Delta-24. Western blot analysis of p21
WAF1 (a and c) or p27
KIP1 (b and d)
expression in HCT116-WT cells transfected with p21
WAF1 (oligos #11 and #12), p27
KIP1 (oligos #5 and #8), or non-targeting control siRNAs.
b-actin was used as loading control. Cell viability of p21
WAF1 or p27
KIP1 siRNA-transfected HCT116-WT (e–g) or HCT116 p53 /  (h–j) cells
followed by WtD (e and h), ONYX-015 (f and i) or Delta-24 (g and j) infection. Viability is expressed as a relative percentage of cells transfected
with non-targeting siRNA control. Error bars indicate s.d. *Po0.05, **Po0.005 compared with negative control.
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16 recently showed that valproic acid upregu-
lates p21
WAF1 expression resulting in inhibition of
adenovirus replication. The exact mechanism by which
CDK inhibitors mediate virus replication remains elusive.
However, it is known that p21
WAF1 interacts with SET
(also called template activating factor TAF1) and
proliferating cell nuclear antigen (PCNA). SET stimulates
the replication of the adenovirus DNA and PCNA
increases DNA replication and repair. Thus, binding of
p21
WAF1 to SET and PCNA may inhibit viral DNA
replication.
25,26
We examined the effects of CDK inhibitors on the
oncolytic adenoviruses ONYX-015 and Delta-24, which
have been developed as therapeutics for the use in
humans. These viruses differ in deletions within the
adenovirus E1-gene region. ONYX-015 is characterized
by a deletion of E1B-55K, whereas Delta-24 carries a
deletion in the E1A region. Our results using p21
WAF1 or
p27
KIP1 siRNAs in HCT116-WT cells show that both
viruses behave similarly in regard to cell killing and virus
production (Figures 3 and 4). HCT116 cells lacking p53
function, showed no difference in cell viability in the
presence or absence of p21
WAF1 or p27
KIP1 siRNAs
(Figure 3). However, replication of adenoviruses was
more productive in these cells when p21
WAF1 or p27
KIP1
expression was suppressed by siRNA before infection. We
expanded our studies using two different cell lines with
non-functioning p53, H1299 and DU-145, and we found
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Figure 4 Replication efficiency of adenovirus in HCT116-WT or HCT116 p53 /  cells transfected with p21
WAF1 or p27
KIP1 siRNAs. HCT116-
WT (a–c) or HCT116 p53 /  (d–f) cells were transfected with p21
WAF1 or p27
KIP1 siRNAs for 48h. The viral titers were determined 72h after
infection with wild-type adenovirus (WtD) (a and d) or ONYX-015 (b and e) or Delta-24 (c and f). Results are shown as means of duplicate
experiments. Error bars represent s.d. *Po0.05, **Po0.005 compared with negative control.
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Cancer Gene Therapythat again virus production but not cell-killing effect were
enhanced after p21 knockdown in cells infected with
oncolytic adenoviruses, ONYX-015 or Delta-24. This suggest
that p53 plays a role in cell killing or virus production when
its downstream, p21, is silenced. Earlier reports have shown
the requirement of p53 in adenovirus-induced cell death.
Geoerger et al.
27 reported that wild-type p53 was associated
with increased anti-tumor activity of ONYX-015 in human
malignant glioma xenografts. Given the complexities of virus
replication and cancer cell environment, understanding the
mechanism that increase oncolytic virus replication and cell
killing is under investigation to provide information relevant
to cancer therapy.
We found that TE7, an esophageal carcinoma cell line
harboring wild-type p53, also showed enhanced viral cell
killing when p21
WAF1 expression was suppressed by
siRNA before infection. The pancreatic cancer cell line,
MIA PaCa-2, does not express p21
WAF1 and was very
susceptible to infection and cell killing by adenoviruses in
the presence or absence of p21
WAF1 siRNA.
Delta-24 carries a deletion within the CR2 region of
E1A, a region necessary for interaction with and
inactivation of RB. Fueyo et al.
28 showed that D54MG
and U-251MG cells treated with replication-deficient
adenoviral vectors expressing either Rb or p21
WAF1 and
infected the cells with Delta-24-RGD had less cell death.
This finding also confirms that expression of p21
WAF1
decreases the cytophatic effects of the Delta-24
adenovirus. Delta-24 has been extensively studied pre-
clinically as a promising therapy for the treatment of
gliomas and ovarian cancer. Recently, a phase I trial of
Delta-24RGD have been approved (Dr J Fueyo, personal
communication).
It is interesting to note that p21
WAF1 has shown to
regulate replication of other viruses. For example,
p21
WAF1 was found to restrict human immunodeficiency
virus type 1 (HIV-1) infection of hematopoietic stem cells.
Zhang et al.
29 showed that p21
WAF1 blocked viral
infection by complexing with HIV-1 integrase and
aborting chromosomal integration.
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Figure 5 Viability of TE7 (b), H1299 (c), DU145 (d) and MIA PaCa-2 (e) cells transfected with p21
WAF1 siRNAs before adenovirus infections.
Cells were transfected with p21
WAF1 siRNA for 48h. Western blotting of p21
WAF1 (a) in cells transfected with p21
WAF1 siRNA or non-targeting
siRNA. b-actin was used as loading control. Cell viability was measured at 72h after infection with wild-type adenovirus (WtD), ONYX-015 or
Delta-24. Data is represented as cell viability relative to untreated cells (equal to 100%). *Po0.05, **Po0.005 compared with negative control.
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Cancer Gene TherapyTaken together, our data illustrate an important role
for p21
WAF1 as modulator of replication of oncolytic
adenoviruses with potential implications for the design of
future clinical trials and improved oncolytic adenoviruses.
p27
KIP1 also reduced killing of HCT116 cells by the
oncolytic adenoviruses used, particularly by WtD and
Delta-24.
p21
WAF1 expression may represent a predictive marker
for efficacy of virus replication in human cancer which
could be useful for selecting patients with the highest
likelihood of tumor response. Furthermore, improved
oncolytic adenoviruses expressing p21
WAF1 siRNA under
the control of tumor or tissue-specific promoters or
liposomal delivery of p21
WAF1 siRNAs might represent
interesting new approaches. Interestingly, antisense oli-
gonucleotides directed against human p21
WAF1 have been
described as a means of improving cancer radiotherapy.
30
In summary, this study highlights the role of
p21
WAF1 as regulators of oncolytic adenovirus replication
in cancer cells. Our findings are potentially relevant for
patient selection as well as for the development of
new therapeutic strategies that include suppression of
p21
WAF1.
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